Ionis Pharmaceuticals (IONS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted an opinion of Tryngolza as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome. The positive opinion is now referred to the European Commission for an approval decision, which is expected by Q4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals publishes results of OASISplus study
- Hold Rating on Ionis Pharmaceuticals Amid Uncertainty Over Olezarsen’s Pancreatitis Endpoint
- Nike upgraded, Sportradar initiated: Wall Street’s top analyst calls
- Ionis Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
- Cautious Optimism for Ionis Pharmaceuticals: Hold Rating Amid Awaited Olezarsen Data